Enblad G - Search Results

1

Antibodies to LMP2A/2B in EBV-carrying malignancies.

Lennette ET, Winberg G, Yadav M, Enblad G, Klein G. Lennette ET, et al. Among authors: enblad g. Eur J Cancer. 1995 Oct;31A(11):1875-8. doi: 10.1016/0959-8049(95)00354-l. Eur J Cancer. 1995. PMID: 8541116

2

Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease.

Enblad G, Sandvej K, Lennette E, Sundström C, Klein G, Glimelius B, Pallesen G. Enblad G, et al. Int J Cancer. 1997 Jul 29;72(3):394-7. doi: 10.1002/(sici)1097-0215(19970729)72:3<394::aid-ijc3>3.0.co;2-k. Int J Cancer. 1997. PMID: 9247279

3

Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma.

Andersson A, Enblad G, Tavelin B, Björkholm M, Linderoth J, Lagerlöf I, Merup M, Sender M, Malmer B. Andersson A, et al. Among authors: enblad g. Br J Cancer. 2008 Mar 11;98(5):1001-5. doi: 10.1038/sj.bjc.6604244. Epub 2008 Feb 12. Br J Cancer. 2008. PMID: 18268493 Free PMC article.

4

Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma.

Fischer M, Bijman M, Molin D, Cormont F, Uyttenhove C, van Snick J, Sundström C, Enblad G, Nilsson G. Fischer M, et al. Among authors: enblad g. Leukemia. 2003 Dec;17(12):2513-6. doi: 10.1038/sj.leu.2403123. Leukemia. 2003. PMID: 14562126

5

Telomerase activity in Hodgkin's disease.

Norrback KF, Enblad G, Erlanson M, Sundström C, Roos G. Norrback KF, et al. Among authors: enblad g. Blood. 1998 Jul 15;92(2):567-73. Blood. 1998. PMID: 9657757

6

Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: a clinico-pathological and immuno-histochemical population-based study of 32 patients.

Amini RM, Enblad G, Sundström C, Glimelius B. Amini RM, et al. Among authors: enblad g. Int J Cancer. 1997 May 16;71(4):510-6. doi: 10.1002/(sici)1097-0215(19970516)71:4<510::aid-ijc2>3.0.co;2-x. Int J Cancer. 1997. PMID: 9178801

7

A more favourable clinical course of lymphoma relapsing after high-dose therapy: evidence of tumour heterogeneity?

Enblad G, Carlson K, Bengtsson M, Hagberg H. Enblad G, et al. Med Oncol. 2000 Aug;17(3):229-32. doi: 10.1007/BF02780534. Med Oncol. 2000. PMID: 10962536

8

Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience.

Amini RM, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Glimelius B. Amini RM, et al. Among authors: enblad g. Eur J Haematol. 2000 Dec;65(6):379-89. doi: 10.1034/j.1600-0609.2000.065006379.x. Eur J Haematol. 2000. PMID: 11168495

9

Serum Levels of Soluble CD 30 and Their Relationship to Tumour Burden and Prognosis in Patients with Hodgkin's Disease.

Enblad G, Amini RM, Sundström C, Glimelius B. Enblad G, et al. Hematology. 1997;2(2):113-23. doi: 10.1080/10245332.1997.11746326. Hematology. 1997. PMID: 27406801

10

The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease.

Molin D, Glimelius B, Sundström C, Venge P, Enblad G. Molin D, et al. Among authors: enblad g. Leuk Lymphoma. 2001 Jul;42(3):457-65. doi: 10.3109/10428190109064602. Leuk Lymphoma. 2001. PMID: 11699410

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results